EPCO-17. METHYLATION ANALYSIS OF MATCHED PRIMARY AND RECURRENT IDHmt ASTROCYTOMA; AN UPDATE FROM THE GLIOMA LONGITUDINAL ANALYSIS NL (GLASS-NL) CONSORTIUM. (12th November 2021)

• Record Type: Journal Article
• Authors: Vallentgoed, Wies; Niers, Anneke; van Garderen, Karin; van den Bent, Martin; Draaisma, Kaspar; de Heer, Iris; Kouwenhoven, Mathilde; Kros, Johan; Martin, Ivonne; Robe, Pierre; Smits, Marion; Tesileanu, Mircea; van Thuijl, Hinke; Verhaak, Roel; Westerman, Bart; van de Wiel, Mark; Ylstra, Bauke; de Leng, Wendy; Wesseling, Pieter; French, Pim
• Is Part Of: Neuro-oncology. Volume 23: Supplement 6(2021)
• Page Start: vi5
• Page End: vi5
• Publication Date: 2021-11-12
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noab196.016
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: The GLASS-NL consortium, was initiated to gain insight into the molecular mechanisms underlying glioma evolution and to identify markers of progression in IDH-mutant astrocytomas. Here, we present the first results of genome-wide DNA-methylation profiling of GLASS-NL samples. 110 adult patients were identified with an IDH-mutant astrocytoma at first diagnosis. All patients underwent a surgical resection of the tumor at least twice, separated by at least 6 months (median 40.9 months (IQR: 24.0, 64.7). In 37% and 18% of the cases, patients were treated with radiotherapy or chemotherapy respectively, before surgical resection of the recurrent tumor. DNA-methylation profiling was done on 235 samples from 103 patients (102 1 st, 101 2 nd, 29 3 rd, and 3 4 th resection). Copy number variations were also extracted from these data. Methylation classes were determined according to Capper et al . Overall survival (OS) was measured from date of first surgery. Of all primary tumors, the methylation-classifier assigned 85 (87%) to the low grade subclass and 10 (10%) to the high grade subclass. The relative proportion of high grade tumors increased ~three-fold at tumor recurrence (32/101, 32%) and even further in the second recurrence (15/29, 52%). Methylation classes were prognostic, both in primary and recurrent tumors. The overall DNA-methylation levels of recurrent samples was lower than that of primary samples. This difference is explained by the increased number of high grade samples at recurrence, since near identical DNA-methylation levels were observed in samples that remained low grade. In an unsupervised analysis, DNA-methylation data derived from primary and first recurrence samples of individual patients mostly (79%) cluster together. Recurrent samples that do not cluster with their primary tumor, form a separate group with relatively low genome-wide DNA-methylation. Our data demonstrate that methylation profiling identifies a shift towards a higher grade at tumor progression coinciding with reduced genome-wide DNA-methylation levels.